Some readers also search for retatrutide weight loss per week
Tsao T, Konopleva M, Sporn MB, Andreeff M
These highlights do not include all the information needed to use WEGOVY Manufacturer Novo Nordisk Pharmaceutical Industries, LP | Novo Nordisk A/S - 25a-B Effective date 2026-06-18 Label type HUMAN PRESCRIPTION DRUG LABEL Version 19 Source monthly-update Hydrated at 2026-07-17 21:41:15 Key Label Information# Uses 1 INDICATIONS AND USAGE WEGOVY injection is indicated in combination with a reduced calorie diet and increased physical activity: to reduce the risk of major adverse cardiovascular (CV) events (CV death, non-fatal myocardial infarction, or non-fatal stroke) in adults with established CV disease and either obesity or overweight
However, GLP-1 medications can also increase the risk of: Pancreatitis Gall bladder disease Gastroparesis (stomach paralysis) Thyroid cancer Kidney problems More research is needed to understand the risks of taking these weight loss drugs long-term
A few signs include: Low libido
SURMOUNT-5 is the only direct head-to-head trial among the three
